Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris

Core Viewpoint - Knight Therapeutics Inc. has received Health Canada approval for WYNZORA, a topical cream for treating psoriasis vulgaris in adults and adolescents aged 12-17, which combines calcipotriol and betamethasone dipropionate to enhance treatment adherence and symptom control [1][3][4]. Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [12]. - The company acquired the Canadian rights to WYNZORA through its acquisition of Paladin Pharma Inc. in June 2025 [2]. Product Details - WYNZORA is a cream-based fixed-dose combination of calcipotriol (0.05 mg/g) and betamethasone dipropionate (0.5 mg/g) designed for the topical treatment of psoriasis vulgaris [1][5]. - The product utilizes MC2's PAD Technology for effective drug delivery, allowing for a convenient aqueous formulation [5]. Clinical Trials and Efficacy - The approval from Health Canada is based on two randomized, investigator-blind, vehicle-controlled trials that demonstrated WYNZORA's superior efficacy compared to a vehicle and non-inferiority to CAL/BDP gel/suspension [6][8]. - In trial MC2-01-C2, WYNZORA showed a 14.6% greater treatment success compared to CAL/BDP gel/suspension, while trial MC2-01-C7 showed a 7.9% difference [8]. Market Impact - The introduction of WYNZORA is expected to improve the quality of life for Canadian patients suffering from psoriasis vulgaris, addressing both adherence and symptom control challenges [3][4]. - Psoriasis affects approximately 1 million Canadians and 125 million people globally, with chronic plaque psoriasis being the most common type [10][11].